Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia von Hartley, Iris R., Roszko, Kelly L., Li, Xiaobai, Pozo, Karen, Streit, Jamie, Rivero, Jaydira, Magone, M. Teresa, Smith, Michaele R., Vold, Roo, Dambkowski, Carl L., Collins, Michael T., Gafni, Rachel I.

Volltext

Reply von Magone, M. Teresa, Hartley, Iris R., FitzGibbon, Edmond, Bishop, Rachel, Arango, Mike, Moran, Susan, Vold, Roo, Rivero, Jaydira del, Pozo, Karen, Streit, Jamie, Roszko, Kelly L., Collins, Michael T., Gafni, Rachel I.

Volltext

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor von Magone, M. Teresa, Hartley, Iris R., Fitzgibbon, Edmond, Bishop, Rachel, Arango, Mike, Moran, Susan, Vold, Roo, Rivero, Jaydira del, Pozo, Karen, Streit, Jamie, Roszko, Kelly L., Collins, Michael T., Gafni, Rachel I.

Volltext

Reply von Magone, M Teresa, Hartley, Iris R, FitzGibbon, Edmond, Bishop, Rachel, Arango, Mike, Moran, Susan, Vold, Roo, Rivero, Jaydira Del, Pozo, Karen, Streit, Jamie, Roszko, Kelly L, Collins, Michael T, Gafni, Rachel I

Volltext